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Stromal cell-derived factor-1 (SDF-1) is a chemokine con-
stitutively expressed and produced in bone marrow (BM) 
stromal cells. It plays a central role in the migration and 
homing of hematopoietic stem cells (HSCs) and hemato-
poietic progenitor cells (HPCs) through signaling via its 
receptor CXCR4. AMD3100 is a small bicyclam molecule, 
which was originally developed as a CXCR4 antagonist that 
could block the entry of the HIV into T cells. It inhibits 
the binding of SDF-1 to CXCR4 and induces peripheral 
mobilization of HSCs and HPCs [1]. AMD3100 safely and 
rapidly mobilizes stem cells in healthy donors and in patients 
with lymphoma and myeloma, and it does so in synergy 
with the granulocyte-colony stimulating factor (G-CSF) [2]. 
A recent phase III clinical study on autologous stem cell 
transplantation showed that a combination of AMD3100 
and G-CSF allowed for the collection of a large number 
of stem cells in fewer apheresis sessions and can help the 
patients in whom mobilization with G-CSF alone was in-
effective [3]. On the basis of these findings, the FDA has 
recently approved the use of AMD3100 in combination 
with G-CSF for stem cell mobilization in patients with 
non-Hodgkin’s lymphoma and multiple myeloma.
Leukemia and myeloma cells also express different levels 
of CXCR4 and respond to SDF-1, resulting in the migration 
and stable localization of these cells in the BM [4]. AMD3100 
induces the segregation of leukemia and myeloma cells in 
the BM microenvironment, thereby mobilizing these cells 
to the peripheral blood and sensitizing them to chemo-
therapy [5]. Studies are underway for testing the use of 
AMD3100 as an adjunct to chemotherapy in patients with 
refractory acute myeloid leukemia (AML) and other hemato-
logic malignancies; if successful, this strategy may be used 
to sensitize leukemic cells to chemotherapy and improve 
clinical outcomes.
SDF-1 alone has a minimal or negligible effects on the 
survival and growth of normal and malignant hematopoietic 
cells  in vitro, but the SDF-1/CXCR4 axis is involved in 
the progression and dissemination of a variety of hemato-
logic malignancies and solid tumors [6]. Patients with multi-
ple myeloma and extramedullary plasmacytoma, which is 
a manifestation of an advanced stage of multiple myeloma, 
show elevated levels of serum SDF-1 and CXCR4 expression, 
respectively. Moreover, BM endothelial cells in multiple 
myeloma patients secrete CXC chemokines, including 
SDF-1, that mediate interactions with the myeloma cells. 
Similar findings have been reported in leukemia patients. 
For example, AML patients with high levels of CXCR4 in 
CD34
＋ cells had a significantly lower survival rate and 
higher probability of relapse than those with low levels 
of CXCR4. A polymorphism in the SDF-1 gene correlated 
with the risk of distant tissue being infiltrated by AML 
cells. Compared to the Philadelphia chromosome 
(Ph)-negative CD34
＋CXCR4
＋ cells, the Ph-positive CD34
＋
CXCR4
＋ cells from chronic myelogenous leukemia patients 
showed limited migration. In addition, SDF-1 has been 
shown to play a role in tumor neoangiogenesis. On the Korean J Hematol 2011;46:209-10.
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basis of these observations, the modulation of the 
SDF-1/CXCR4 axis has been suggested to influence the bio-
logical characteristics and disease course of hematologic 
malignancies.
Contradictory to early studies, CXCR4 antagonists have 
been shown to inhibit the survival and proliferation of leuke-
mia and myeloma cells in vitro. AMD3100 and TC140012, 
another CXCR4 antagonist, significantly inhibited stro-
ma-dependent proliferation of leukemia cells in a population 
of patients with acute lymphoblastic leukemia. In addition, 
AMD3100 and TC140012 were shown to enhance the cyto-
toxic and antiproliferative effects of the cytotoxic agents 
vincristine and dexamethasone [7]. AMD3100 arrested pro-
liferation in AML cell lines and triggered changes that mim-
icked differentiation, including morphological changes and 
the expression of myeloid differentiation antigens [8]. A 
recent study has shown that another CXCR4 antagonist, 
BKT140 4F-benzoyl-TN14003 (BKT140), exhibited CXCR4- 
dependent preferential cytotoxicity toward malignant cells 
of hematopoietic origin. BKT140 significantly and preferen-
tially stimulated apoptotic cell death in multiple myeloma 
cells. BKT140 treatment induced morphological changes and 
phosphatidylserine externalization; it also decreased mi-
tochondrial membrane potential, caspase-3 activation, sub- 
G1 arrest, and DNA double-stranded breaks. In vivo, sub-
cutaneous injection of BKT140 significantly reduced the 
growth of human AML and multiple myeloma xenografts 
in a dose-dependent manner. Compared to the tumor sam-
ples obtained from animals not treated with BKT140, those 
obtained from the animals treated with BKT140 were small-
e r  i n  s i z e  a n d  l o w e r  i n  w e i g h t  a n d  h a d  l a r g e r  n e c r o t i c  
areas and high apoptotic scores [9]. In this issue of the 
Korean Journal of Hematology, Kim et al. report that higher 
concentrations of AMD3100 enhanced the proliferation of 
AML cells during the early course of in vitro incubation. 
Conversely, after 5-7 days of culture, AMD3100 decreased 
the number of AML cells and induced cell apoptosis more 
rapidly than the control did [10].
In summary, recent studies have suggested that CXCR4 
antagonists may potentially be used in the treatment of 
hematologic malignancies not only as stem cell mobilizers 
for transplantation and sensitizers to chemotherapy but also 
as direct cytotoxic agents.
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